AMICUS THERAPEUTICS INC (FOLD)

US03152W1099 - Common Stock

10.45  -0.1 (-0.95%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FOLD. FOLD was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of FOLD have multiple concerns. FOLD is valued quite expensively, but it does show have an excellent growth rating.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

FOLD had negative earnings in the past year.
In the past year FOLD has reported a negative cash flow from operations.
In the past 5 years FOLD always reported negative net income.
FOLD had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -19.48%, FOLD belongs to the top of the industry, outperforming 83.08% of the companies in the same industry.
FOLD has a Return On Equity (-94.61%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -19.48%
ROE -94.61%
ROIC N/A
ROA(3y)-26.61%
ROA(5y)-30.6%
ROE(3y)-122.83%
ROE(5y)-108%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 90.65%, FOLD belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
FOLD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for FOLD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.96%
GM growth 5Y1.49%

More info and screens

3

2. Health

2.1 Basic Checks

FOLD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FOLD has more shares outstanding
The number of shares outstanding for FOLD has been increased compared to 5 years ago.
Compared to 1 year ago, FOLD has an improved debt to assets ratio.

2.2 Solvency

FOLD has an Altman-Z score of -1.13. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
FOLD has a Altman-Z score (-1.13) which is in line with its industry peers.
A Debt/Equity ratio of 2.42 is on the high side and indicates that FOLD has dependencies on debt financing.
FOLD's Debt to Equity ratio of 2.42 is on the low side compared to the rest of the industry. FOLD is outperformed by 83.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF N/A
Altman-Z -1.13
ROIC/WACCN/A
WACC9.09%

2.3 Liquidity

FOLD has a Current Ratio of 2.88. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FOLD (2.88) is worse than 67.52% of its industry peers.
FOLD has a Quick Ratio of 2.52. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.52, FOLD is not doing good in the industry: 70.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.52

More info and screens

7

3. Growth

3.1 Past

FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.80%, which is quite impressive.
FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.32%.
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.36% yearly.
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q42.11%
Revenue 1Y (TTM)21.32%
Revenue growth 3Y15.25%
Revenue growth 5Y34.36%
Revenue growth Q2Q30.63%

3.2 Future

The Earnings Per Share is expected to grow by 46.29% on average over the next years. This is a very strong growth
Based on estimates for the next years, FOLD will show a very strong growth in Revenue. The Revenue will grow by 28.25% on average per year.
EPS Next Y100.89%
EPS Next 2Y67.07%
EPS Next 3Y61.15%
EPS Next 5Y46.29%
Revenue Next Year33.24%
Revenue Next 2Y30.8%
Revenue Next 3Y33.59%
Revenue Next 5Y28.25%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
FOLD is valuated quite expensively with a Price/Forward Earnings ratio of 2307.45.
FOLD's Price/Forward Earnings ratio is rather cheap when compared to the industry. FOLD is cheaper than 93.50% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.32, FOLD is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 2307.45

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
FOLD's earnings are expected to grow with 61.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.07%
EPS Next 3Y61.15%

More info and screens

0

5. Dividend

5.1 Amount

FOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMICUS THERAPEUTICS INC

NASDAQ:FOLD (4/18/2024, 9:48:06 AM)

10.45

-0.1 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.09B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2307.45
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.48%
ROE -94.61%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 90.65%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.88
Quick Ratio 2.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)37.8%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y100.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.32%
Revenue growth 3Y15.25%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y